These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

749 related items for PubMed ID: 26351322

  • 1. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
    Whittaker SR, Cowley GS, Wagner S, Luo F, Root DE, Garraway LA.
    Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
    [Abstract] [Full Text] [Related]

  • 2. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB.
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [Abstract] [Full Text] [Related]

  • 3. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
    Zhang P, Kawakami H, Liu W, Zeng X, Strebhardt K, Tao K, Huang S, Sinicrope FA.
    Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L.
    J Exp Clin Cancer Res; 2018 Jul 09; 37(1):140. PubMed ID: 29986755
    [Abstract] [Full Text] [Related]

  • 5. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.
    Nature; 2010 Mar 18; 464(7287):431-5. PubMed ID: 20130576
    [Abstract] [Full Text] [Related]

  • 6. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 7. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer.
    Hong SP, Ahn SK.
    Life Sci; 2017 Aug 15; 183():37-44. PubMed ID: 28645859
    [Abstract] [Full Text] [Related]

  • 8. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
    Song Q, Sun X, Guo H, Yu Q.
    Oncotarget; 2017 Jan 17; 8(3):5003-5015. PubMed ID: 28002807
    [Abstract] [Full Text] [Related]

  • 9. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
    Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA.
    Cancer Discov; 2012 Mar 17; 2(3):227-35. PubMed ID: 22448344
    [Abstract] [Full Text] [Related]

  • 10. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
    Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N.
    Cancer Cell; 2014 May 12; 25(5):697-710. PubMed ID: 24746704
    [Abstract] [Full Text] [Related]

  • 11. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di Nicolantonio F, Bardelli A.
    Cell Rep; 2014 Sep 11; 8(5):1475-83. PubMed ID: 25199829
    [Abstract] [Full Text] [Related]

  • 12. Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.
    Lochhead PA, Clark J, Wang LZ, Gilmour L, Squires M, Gilley R, Foxton C, Newell DR, Wedge SR, Cook SJ.
    Cell Cycle; 2016 Sep 11; 15(4):506-18. PubMed ID: 26959608
    [Abstract] [Full Text] [Related]

  • 13. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, Young RJ, Brajanovski N, Cameron DP, Walker R, Sanij E, Poortinga G, Hannan RD, Pearson RB, Hicks RJ, McArthur GA, Sheppard KE.
    Int J Cancer; 2018 May 15; 142(10):2139-2152. PubMed ID: 29243224
    [Abstract] [Full Text] [Related]

  • 14. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S, Mukherji D, Shamseddine A.
    Int J Mol Sci; 2015 Sep 23; 16(9):22976-88. PubMed ID: 26404261
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ, Le K, Hartsough EJ, Aplin AE.
    Pigment Cell Melanoma Res; 2014 May 23; 27(3):479-84. PubMed ID: 24422853
    [Abstract] [Full Text] [Related]

  • 16. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B, Ritt DA, Morrison DK, Der CJ, Cox AD.
    J Biol Chem; 2016 Aug 19; 291(34):17804-15. PubMed ID: 27226552
    [Abstract] [Full Text] [Related]

  • 17. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N.
    Nature; 2010 Mar 18; 464(7287):427-30. PubMed ID: 20179705
    [Abstract] [Full Text] [Related]

  • 18. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
    Hata AN, Rowley S, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Ji F, Jung J, Light M, Lee JS, Debussche L, Sidhu S, Sadreyev RI, Watters J, Engelman JA.
    Oncogene; 2017 Nov 23; 36(47):6581-6591. PubMed ID: 28783173
    [Abstract] [Full Text] [Related]

  • 19. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
    Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA.
    Cancer Discov; 2014 Jan 23; 4(1):61-8. PubMed ID: 24265154
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors.
    Yen I, Shanahan F, Merchant M, Orr C, Hunsaker T, Durk M, La H, Zhang X, Martin SE, Lin E, Chan J, Yu Y, Amin D, Neve RM, Gustafson A, Venkatanarayan A, Foster SA, Rudolph J, Klijn C, Malek S.
    Cancer Cell; 2018 Oct 08; 34(4):611-625.e7. PubMed ID: 30300582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.